What questions should a plastic surgery practice ask before adding exosomes?

Eight: who owns the protocol, which studies are human topical and which are animal or surgical, whether the use stays topical or becomes an IND question, which facility rules apply, what the evidence leaves open, what the lot documents show, how consent and records are written, and how storage and adverse events are handled. Stack and colleagues pooled 39 human studies with nonstandardized protocols in 2026 [1].

What does the research say about exosomes with fat grafting?

The evidence is animal. Ghiasloo and colleagues found seven studies, all in mice, covering 294 animals, with higher retention in vesicle-enriched grafts and clinical relevance still to be determined [6]. Chen and colleagues reported 56.4 percent retention with exosomes against 40.7 percent with saline at 10 weeks in mice [7], and Jiang and colleagues found no difference at 8 weeks in cryopreserved grafts [10].

What should a plastic surgeon exosome protocol include?

The supervising surgeon and each operator, the published topical sequence it follows, a statement that the material is applied topically after the procedure and nowhere else, the lot documents, the consent wording, the photography standard, the freezer log and the adverse event route. Kwon and colleagues described the resurfacing sequence in a double-blind split-face trial of 25 adults [11].

What do studies report about exosomes after surgery and other procedures?

The controlled human data are post-procedure and topical: Kwon and colleagues reported milder erythema and shorter downtime after fractional CO2 in 25 adults [11], and Park GH and colleagues reported higher improvement scores after microneedling in 28 adults [12]. Duncan and colleagues listed postprocedure recovery among the applications discussed in the 2026 surgical supplement [4], and Gaebe and colleagues rated the overall certainty low or very low [2].

Do accredited office surgery suites change the exosome question?

The facility rules the practice already follows carry over to the new step. Gupta and colleagues compared 183,914 aesthetic procedures and reported 30-day major complication rates of 1.3 percent in accredited office suites, 1.9 percent in ambulatory centers and 2.4 percent in hospitals [15], and state boards publish office surgery standards the practice registers under.

Are exosomes FDA approved for plastic surgery?

The FDA stated in 2019 that there are currently no FDA-approved exosome products [18], and its consumer alert states that exosome products intended to treat diseases or conditions in humans require FDA approval [19]. Abraham and Wilson wrote for facial plastic surgeons in 2025 that exosomes should be considered experimental until regulatory approval and robust clinical validation [16].

What exosome documentation should a plastic surgery practice keep?

The signed protocol, the sorted evidence file, the accreditation certificate, the lot documents read against MISEV2023 [17], a consent form that matches the website, the chart entry with the lot number, the freezer log and the adverse event route. Knauer and colleagues reported minimal processing information across 20 commercial products in 2026 [3].

How does a plastic surgery practice report an exosome adverse event?

Through the FDA’s MedWatch program, which accepts voluntary reports from health professionals covering biologics, devices and cosmetics, with the lot number in the report and the supplier notified [21]. Park KY described four women with persistent nodules and granulomatous inflammation after intradermal injection of products sold for topical use [14].

6 November 2026 · Updated November 2026 · 16 min read

Adding Exosomes to a Plastic Surgery Practice: Eight Questions to Settle First

Adding exosomes to a plastic surgery practice: a surgeon and manager checklist on where topical aftercare ends, which facility rules apply and the lot records.

ExosomesPlastic SurgeryFat Grafting ResearchSurgical RecoveryFacility AccreditationINDDocumentationPractitioner Guides

Benn Bluestein-Veyra, M.Sc. Organic Chemistry | ExaVeyra Sciences

Cited sources

A plastic surgery practice adding exosomes works with two different literatures: a human literature of topical post-procedure studies, pooled in a 2026 meta-analysis of 39 human studies whose authors reported a 20.2 percent average wrinkle reduction among the skin studies alongside nonstandardized protocols [1], and an animal literature on fat grafting, in which a 2021 systematic review found seven studies, all in mice, covering 294 animals [6]. Where a practice draws the line between those two is the first question it settles.

The questions below are framed for the board-certified plastic surgeon, or the administrator working with one, in a practice that operates an accredited office suite or ambulatory center and already offers energy-based resurfacing. Each of eight questions names why it matters and what a documented answer looks like. ExaVeyra Sciences supplies exosome material for topical aesthetic use by licensed practitioners, and for laboratory research and clinical research conducted under an IND, and every clinical decision described here belongs to the surgeon.

human topical studies pooled in the 2026 meta-analysis, which noted nonstandardized protocols, read in question 2

294

mice across the seven fat-grafting vesicle studies in the 2021 systematic review, with no human study located

183,914

aesthetic procedures compared across accredited office suites, ambulatory centers and hospitals in a 2017 cohort

Regulatory status

The FDA stated in its 2019 public safety notification that there are currently no FDA-approved exosome products [18], and its consumer alert states that, as a general matter, exosome products intended to treat diseases or conditions in humans require FDA approval [19]. ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners, and for laboratory research and clinical research conducted under an IND, with the lot number on every vial and a certificate of analysis for every lot. Whether and how any material is used in a given practice is the surgeon’s decision.

1. Which surgeon owns the protocol, and which steps are delegated to nursing or aesthetic staff?

In a surgical practice the topical step usually belongs to the resurfacing or post-procedure skincare protocol run by nursing or aesthetic staff, with the surgeon as medical director. The written protocol names the surgeon who signs it, the staff member who performs the resurfacing session and the topical step, and the supervision level the state practice act sets for each.

The human studies place the step after a procedure performed by a clinician. Kwon and colleagues applied a topical gel after each of three fractional CO2 sessions in a double-blind split-face trial of 25 adults [11], and Park GH and colleagues applied a solution after three microneedling sessions in 28 adults [12], both in physician-led settings.

A documented answer is a signed protocol that attaches to the practice’s existing resurfacing and aftercare documents, names each operator, and records the state board rule the delegation rests on. The state guides linked below summarize those rules, and the board remains the authority.

2. Which parts of the published evidence are topical post-procedure studies, and which are animal or surgical?

The human evidence is topical and post-procedure. Gaebe and colleagues reviewed 16 studies with 503 participants in 2026, reported no serious adverse events and rated certainty low or very low [2], and Stack and colleagues pooled 39 human studies with heterogeneity and nonstandardized protocols [1]. Wang, Bajwa and Rivers reported that the serious events in the dermatology literature followed injection [13].

The fat grafting evidence is animal. Chen and colleagues reported graft retention of 56.4 percent with exosomes against 40.7 percent with saline at 10 weeks in mice [7], Han and colleagues reported higher graft weight and better perfusion in nude mice with hypoxia-preconditioned exosomes [8], and Zhu, Hong and Chang reported higher volume retention than control at weeks 4 and 8 in nude mice in 2025 [9]. Jiang and colleagues found early gains in cryopreserved grafts and no difference at 8 weeks [10].

The surgical journal supplement of 2026 collects both strands. Duncan and colleagues listed postprocedure recovery and adipose tissue volumization among the discussed applications and noted variable purity across isolation methods [4], and Lacerna Kimbrell reported a single-surgeon retrospective series of 101 patients in which separate, nonrandomized groups were compared after helium plasma resurfacing: a mean of 10.74 days to re-epithelialization with topical application against 15.78 without it after resurfacing alone, and 10.24 against 15.48 days with a concurrent facelift [5]. A documented answer sorts each study the practice relies on into human topical, animal, or retrospective surgical.

3. Does the intended use stay topical and post-procedure, or does it cross into an IND question?

This is the question that distinguishes a surgical practice from a med spa. A topical step on resurfaced skin after the procedure follows the published human sequence [11, 12]. Mixing vesicle material with a fat graft, applying it to a surgical bed or injecting it is a clinical investigation of an unapproved biological product, and 21 CFR 312.20 requires a sponsor to submit an IND before such an investigation begins [20].

Abraham and Wilson wrote for facial plastic surgeons in 2025 that no exosome product is FDA-approved for medical use and that exosomes should be considered experimental until regulatory approval and robust clinical validation [16]. Ghiasloo and colleagues wrote that the clinical relevance of vesicle-enriched fat grafting remained to be determined after reviewing the mouse studies [6].

A documented answer states in the protocol that the material is applied topically after the procedure and nowhere else, and routes any surgeon interested in a fat grafting or intraoperative study to the pre-IND process described in the clinic-launch resource linked below. ExaVeyra supplies exosome material for clinical research conducted under an IND, with the sponsor’s IND number and protocol confirmed before any supply.

4. Which facility rules apply where the procedure is performed?

Surgical practices already operate under facility accreditation and state office-surgery rules, and the exosome step inherits them. Gupta and colleagues compared 183,914 aesthetic procedures across accredited office-based suites, ambulatory surgery centers and hospitals and reported 30-day major complication rates of 1.3, 1.9 and 2.4 percent respectively, with a lower adjusted risk in accredited office suites [15].

State boards of medicine publish office surgery standards that set levels of surgery, registration and equipment requirements; the Florida Board of Medicine’s Standard of Care for Office Surgery rule, 64B8-9.009, last amended effective 16 September 2024, is one example [22], and the state guides linked below carry the primary sources. A documented answer records the facility’s accreditation body and expiry date, the state office-surgery registration where one applies, and the room in which the topical step is performed.

Question	Why it matters	What a documented answer looks like
Which surgeon owns the protocol, and who performs each step?	The human studies were run in physician-led settings after a clinician-performed procedure [11, 12]	A signed protocol attached to the resurfacing and aftercare documents, naming each operator
Which studies are human topical, which are animal, and which are retrospective surgical?	Fat grafting evidence is mouse data [6, 7, 8, 9, 10]; the facelift-adjacent series is retrospective [5]	A sorted evidence file with each study labeled by design
Does the use stay topical, or is it an IND question?	A clinical investigation of an unapproved biologic needs an IND before it begins [20]	A protocol statement that the material is applied topically after the procedure and nowhere else
Which facility rules apply?	Complication rates differed by accredited facility type in 183,914 procedures [15]	Accreditation body and expiry, state office-surgery registration, and the room named
What do the lot documents show?	Commercial products carried minimal processing information [3]	The certificate of analysis, characterization panel and cold-chain records, read against MISEV2023 [17]
How are consent, photography and the operative record written?	The FDA states that exosomes used for diseases and conditions are regulated as drugs and biologics [18]	A consent form that matches the website, standardized photographs and a chart entry with the lot number
How is the material stored, and how is an adverse event reported?	MedWatch accepts voluntary reports from health professionals [21]	A freezer log, an excursion plan and a named reporter who includes the lot number

5. Which questions does the published evidence leave open?

A surgeon explaining the service to a patient, a peer or an accreditation surveyor is on firmer ground when the gaps are stated with the literature. The points below set out what the published evidence does not yet show.

Certainty is low: Gaebe and colleagues rated the evidence across 16 studies and 503 participants as low or very low certainty [2].
Fat grafting data are animal: the seven studies in the 2021 systematic review were all in mice [6], and no human fat grafting study of vesicle material was located.
The animal data are not uniform: Jiang and colleagues found no difference at 8 weeks in cryopreserved grafts [10].
The facelift-adjacent series is retrospective: Lacerna Kimbrell’s 101 patients were reviewed from one practice over eight years, without randomization or blinding [5].
Protocols are not standardized: Stack and colleagues reported heterogeneity across 39 human studies, so no interval or quantity is established [1].
Products differ: Knauer and colleagues found minimal information on isolation, processing or shelf life across 20 commercial products [3].
Route matters: the serious events in the literature followed injection [13, 14], and no study compares outcomes by surgical facility type.
No society position was located: a PubMed search on the audit date found no American Society of Plastic Surgeons or Aesthetic Society position statement on exosome products.

6. What does the supplier’s documentation show, and who reads it?

Knauer and colleagues surveyed 20 commercial topical exosome products in 2026 and reported minimal information on isolation, processing or shelf life [3], and Duncan and colleagues noted that isolation methods yield variable purity [4]. A surgical practice already reads implant and device documentation, and the lot documents join that routine.

The MISEV2023 guideline sets out reporting headings for separation method, particle size and concentration, marker proteins and morphology, a neutral checklist for a certificate of analysis [17]. ExaVeyra prints the lot number on every vial, generates a certificate of analysis for every lot with serology, and makes the certificate, characterization panel and cold-chain records available on request.

A documented answer files the lot documents with the receiving record, names the person who read them, and records that the labeling, the protocol and the consent form describe the same topical use.

The consent form for the resurfacing procedure names the topical step as aftercare the surgeon chose, in the same words the website uses. The FDA notification states that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products [18], so consent language that describes appearance and recovery as the practice measures them, and names no condition, keeps the documents consistent.

Surgical practices already photograph to a standard, and the same positions, lighting and background serve the new step. The retrospective series measured days to re-epithelialization [5], and a practice that records the same endpoint at fixed visits builds a comparable record of its own.

A documented chart entry carries the procedure, the device settings, the lot number of the material applied, the operator and the supervising surgeon, with the lot number in a discrete field so every patient who received a given lot can be found.

8. How is the material stored, and how is an adverse event reported?

ExaVeyra orders ship overnight frozen on dry ice and arrive in 1 to 3 business days, and the receiving procedure checks the dry ice, records the arrival time and lot number, and moves the vials to the freezer before anything else happens. The material is stored at the temperature on the manufacturer’s handling instructions, with a daily temperature log and an excursion plan that lists affected lot numbers.

The reviews report that adverse events were uncommon, with no serious adverse events in the 2026 systematic review, and that the serious events followed injection [2, 13]. The FDA’s MedWatch program accepts voluntary reports from health professionals covering biologics, devices and cosmetics [21], and the consumer alert points patients to the same route [19]. A documented answer names the reporter, requires the lot number in every report, notifies the supplier, and files the report with the chart.

A surgical practice adds the topical step to a facility record, an operative record and an accreditation file it already keeps. Stating in writing where the topical step ends and a study begins is what makes the service defensible.

A verified account places the documents in the file before the first case

The checklist below gathers the eight questions into items a practice administrator can tick off. Each one has an owner in the table above.

The signed protocol attaches to the resurfacing and aftercare documents and names each operator and the supervising surgeon.
The evidence file labels each study as human topical, animal, or retrospective surgical.
The protocol states that the material is applied topically after the procedure and nowhere else, and any study interest is routed to the IND process.
The accreditation certificate, its expiry date and any state office-surgery registration are on file.
The certificate of analysis, characterization panel and cold-chain records for the current lot have been requested and read.
The consent form, website and chart template describe the same service, and the chart has a discrete lot field.
The photography standard and the recovery endpoints the practice will record are written down.
The freezer log is running, and the adverse event route names a reporter who includes the lot number.

A surgical practice that applies for a verified account can have these documents on file before the first case. Anyone may ask the scientific team a question or apply without an NPI, review takes 1 to 3 business days, and NPI verification gives access to the practitioner portal, product documentation and pricing for each available format.

Practices that draw the line between aftercare and investigation in writing from the start are well placed to run the topical step with confidence today and to sponsor the controlled surgical studies the field is waiting for.

Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

References

1.Stack ER, Spongberg C, Braud SC, Stanton WN, Elway M. Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthet Surg J. 2026;46(12 Suppl 2):S13-S25. PMID 41800726. doi:10.1093/asj/sjaf178Systematic review and random-effects meta-analysis, searches to February 2025; 39 human studies. Carries in this article: a pooled facial wrinkle reduction of 20.2 percent, with heterogeneity and nonstandardized protocols noted by the authors. Disclosure: published in the Aesthetic Surgery Journal supplement on exosomes; no funding statement in the PubMed record.
2.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches to June 2025; 16 studies, 503 participants. Carries in this article: no serious adverse events were reported, risk of bias was moderate to critical and certainty was low or very low. Disclosure: academic authors (Canada); no conflict statement in the PubMed record.
3.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review of 18 human studies plus a market survey of 20 commercial topical exosome products. Carries in this article: the products carried minimal information on isolation, processing or shelf life, the reason the practice reads lot documents before the first case. Disclosure: academic authors (USA); no conflict statement in the PubMed record.
4.Duncan DI, Tiryaki T, Suwanchinda A, Chernoff G, Cohen S. Exosomes in Aesthetic Medicine: An Overview. Aesthet Surg J. 2026;46(12 Suppl 2):S1-S12. PMID 41800722. doi:10.1093/asj/sjaf259Narrative overview opening the Aesthetic Surgery Journal supplement on exosomes. Carries in this article: the applications the surgical literature discusses (photoaging, scar remodeling, hair, wound healing, postprocedure recovery and adipose tissue volumization), the variable purity of isolation methods, and the authors’ statement that regulatory frameworks differ by jurisdiction. Disclosure: the authors are practicing aesthetic surgeons and physicians; conflicts are listed in the article.
5.Lacerna Kimbrell M. Enhanced Healing and Outcomes With Human Dermal Fibroblast Exosomes: Case Series Combining Deep Helium Radiofrequency Plasma Skin Resurfacing, Facelifts, and Exosomes. Aesthet Surg J. 2026;46(12 Suppl 2):S73-S81. PMID 41800725. doi:10.1093/asj/sjaf214Single-surgeon retrospective review, July 2017 to September 2025; 101 patients in four groups (resurfacing alone with or without topical exosomes, resurfacing plus facelift with or without topical exosomes). Carries in this article: separate nonrandomized groups, with a mean of 10.74 days to re-epithelialization with topical exosome application against 15.78 without after resurfacing alone, and 10.24 against 15.48 with a concurrent facelift, the only located facelift-adjacent series, and its retrospective single-practice design. Disclosure: single author; conflicts as listed in the article.
6.Ghiasloo M, De Wilde L, Singh K, Tonnard P, Verpaele A, De Wever O, et al. A Systematic Review on Extracellular Vesicles-Enriched Fat Grafting: A Shifting Paradigm. Aesthet Surg J. 2021;41(11):NP1695-NP1705. PMID 33319908. doi:10.1093/asj/sjaa362Systematic review of Embase, PubMed and Cochrane; seven studies, all in mice, 294 animals. Carries in this article: vesicle-enriched grafts showed higher retention than untreated grafts and retention similar to cell-assisted grafts, with earlier revascularization, and the authors wrote that clinical relevance remained to be determined. Disclosure: plastic surgery and cancer research authors (Belgium); none stated in the PubMed record.
7.Chen B, Cai J, Wei Y, Jiang Z, Desjardins HE, Adams AE, et al. Exosomes Are Comparable to Source Adipose Stem Cells in Fat Graft Retention with Up-Regulating Early Inflammation and Angiogenesis. Plast Reconstr Surg. 2019;144(5):816e-827e. PMID 31385891. doi:10.1097/PRS.0000000000006175Controlled animal study; C57BL mice, 16 per group, fat mixed with exosomes, source cells or saline and harvested at 3 and 10 weeks. Carries in this article: retention of 56.4 percent in the exosome group and 50.9 percent with cell-assisted transfer against 40.7 percent with saline at week 10, in mice. Disclosure: none stated in the PubMed record.
8.Han YD, Bai Y, Yan XL, Ren J, Zeng Q, Li XD, et al. Co-transplantation of exosomes derived from hypoxia-preconditioned adipose mesenchymal stem cells promotes neovascularization and graft survival in fat grafting. Biochem Biophys Res Commun. 2018;497(1):305-312. PMID 29428734. doi:10.1016/j.bbrc.2018.02.076Controlled animal study; nude mouse subcutaneous fat grafting with exosomes injected around the graft, assessed from 2 to 8 weeks with Doppler flowmetry and CD31 staining. Carries in this article: higher graft weight, more perilipin-positive adipocytes and better perfusion in the exosome groups, with hypoxia-preconditioned exosomes performing best, in mice. Disclosure: none stated in the PubMed record.
9.Zhu Y, Hong KY, Chang H. Exosome-Mediated Enhancement of Fat Graft Retention: A Comparative Preclinical Study with Stromal Vascular Fraction. Aesthetic Plast Surg. 2025;49(24):6912-6922. PMID 41249525. doi:10.1007/s00266-025-05350-5Controlled animal study; human fat grafted into nude mice with saline, stromal vascular fraction cells or adipose stromal cell exosomes, imaged by micro-CT at weeks 4 and 8. Carries in this article: higher volume retention in the exosome group than control at both time points, with less inflammation and more angiogenesis than the cell group, in mice. Disclosure: none stated in the PubMed record.
10.Jiang XY, Li FW, Chen YQ, Fang JR, Luo SK, Wang HB. Exosomes Derived from Human Adipose-Derived Stem Cells Cannot Distinctively Promote Graft Survival in Cryopreservation Fat Grafting. Aesthetic Plast Surg. 2023;47(5):2117-2129. PMID 37400586. doi:10.1007/s00266-023-03457-1Controlled animal study; 24 nude mice, fresh or one-month cryopreserved fat with weekly exosomes or buffer, harvested at 1, 2, 4 and 8 weeks. Carries in this article: better integrity of cryopreserved grafts at early time points and no difference at 8 weeks, the counterexample that keeps the animal literature from reading as uniform. Disclosure: none stated in the PubMed record.
11.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized, split-face trial over 12 weeks with three fractional CO2 sessions (Korea); n = 25. Carries in this article: the published sequence of a topical exosome gel applied after a resurfacing session, with greater scar improvement, milder erythema and shorter downtime reported on the exosome side. Disclosure: the exosome and control gels were manufactured and supplied by the exosome manufacturer; the authors declared no conflicts of interest.
12.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face study over 12 weeks, three microneedling sessions three weeks apart, saline control side (Korea); n = 28. Carries in this article: the published sequence after microneedling, with higher aesthetic improvement scores and instrument-measured gains on the exosome side. Disclosure: National Research Foundation of Korea grants listed in the PubMed record.
13.Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID 41931695. doi:10.36849/jdd.9610PRISMA-ScR scoping review of human studies published 2020 to 2025; 17 studies. Carries in this article: adverse events were uncommon, and the serious events listed (granulomas, necrosis, allergic reactions) followed injection, the reason the surgical protocol separates a topical post-procedure step from any other route. Disclosure: none stated for the authors in the PubMed record.
14.Park KY. Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series. J Cosmet Dermatol. 2025;24(10):e70520. PMID 41097876. PMC12528963. doi:10.1111/jocd.70520Case series; adult women after intradermal injection of exosome-containing cosmetic products in nonclinical settings (South Korea); n = 4. Carries in this article: persistent erythema, nodules and granulomatous inflammation reported when products sold for topical use were used by another route. Disclosure: the author declared no conflicts of interest.
15.Gupta V, Parikh R, Nguyen L, Afshari A, Shack RB, Grotting JC, et al. Is Office-Based Surgery Safe? Comparing Outcomes of 183,914 Aesthetic Surgical Procedures Across Different Types of Accredited Facilities. Aesthet Surg J. 2017;37(2):226-235. PMID 27553613. doi:10.1093/asj/sjw138Prospective cohort from an insurance database, 2008 to 2013; 129,007 patients, 183,914 procedures across accredited office-based suites, ambulatory surgery centers and hospitals. Carries in this article: 30-day major complication rates of 1.3, 1.9 and 2.4 percent respectively, with a lower adjusted risk in accredited office suites, the reason facility accreditation is a question in its own right. Disclosure: database access through the cohort’s insurer; conflicts as listed in the article.
16.Abraham MT, Wilson J 4th. Exosomes in Facial Plastic Surgery. Facial Plast Surg. 2025;41(2):274-276. PMID 39832778. doi:10.1055/a-2510-6807Short review in a facial plastic surgery journal. Carries in this article: the authors’ statement that no exosome product is FDA-approved for medical use and that exosomes should be considered experimental until regulatory approval and robust clinical validation, written for surgeons. Disclosure: none stated in the PubMed record.
17.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, compiled with ISEV task forces and more than 1,000 researchers. Carries in this article: the reporting headings (separation, particle size and concentration, marker proteins, morphology) a practice reads a certificate of analysis against. Disclosure: many consortium authors list EV company affiliations, declared in full in the article.
18.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 4 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products, and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products.
19.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. July 22, 2020 (content current as of 04/09/2024; verified 4 November 2026). https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: as a general matter, exosome products intended to treat diseases or conditions in humans require FDA approval, there are currently no FDA-approved exosome products, and adverse events may be reported through MedWatch.
20.U.S. Food and Drug Administration. 21 CFR 312.20, Requirement for an IND. Text verified on eCFR 4 November 2026 (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.20). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.20Codified regulation. Carries in this article: a sponsor must submit an IND before conducting a clinical investigation with an investigational new drug subject to 312.2(a), the route any intraoperative or fat-graft study of vesicle material would take.
21.U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Content current as of 11/03/2026; verified 4 November 2026. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-programAgency reporting program page. Carries in this article: the voluntary reporting route for health professionals, patients and consumers covering biologics, medical devices and cosmetics, the route a practice documents for any adverse event recorded with its lot number.
22.Florida Board of Medicine. Florida Administrative Code rule 64B8-9.009, Standard of Care for Office Surgery. Latest amendment effective 9/16/2024; read on the Florida Administrative Code site 5 November 2026 (https://www.flrules.org/gateway/ruleNo.asp?id=64B8-9.009). The federal status of any material used in the office suite is set out by the FDA at fda.gov in the notification and alert cited at [18] and [19].State board rule. Carries in this article: an example of a state office-surgery standard that sets levels of surgery, registration and equipment requirements, and its latest effective date, the facility rules a surgical practice already follows when it adds a topical step.

Ask your practitioner how their exosomes are tested

Lab analysis shows what is in a lot: particle counts, vesicle markers, sterility and how the material was stored. A practice that sources carefully can answer these questions from its supplier’s records.

See the questions to ask

Frequently Asked Questions

What questions should a plastic surgery practice ask before adding exosomes?: Eight: who owns the protocol, which studies are human topical and which are animal or surgical, whether the use stays topical or becomes an IND question, which facility rules apply, what the evidence leaves open, what the lot documents show, how consent and records are written, and how storage and adverse events are handled. Stack and colleagues pooled 39 human studies with nonstandardized protocols in 2026 [1].
What does the research say about exosomes after a facelift?: One retrospective series was located. Lacerna Kimbrell reviewed 101 patients from a single practice over eight years and compared separate groups after helium plasma resurfacing: a mean of 10.74 days to re-epithelialization with topical exosome application against 15.78 without it after resurfacing alone, and 10.24 against 15.48 days with a concurrent facelift [5]. The groups were not randomized or blinded.
What does the research say about exosomes with fat grafting?: The evidence is animal. Ghiasloo and colleagues found seven studies, all in mice, covering 294 animals, with higher retention in vesicle-enriched grafts and clinical relevance still to be determined [6]. Chen and colleagues reported 56.4 percent retention with exosomes against 40.7 percent with saline at 10 weeks in mice [7], and Jiang and colleagues found no difference at 8 weeks in cryopreserved grafts [10].
Can a plastic surgeon use exosomes during surgery?: Applying vesicle material to a surgical bed, mixing it with a fat graft or injecting it is a clinical investigation of an unapproved biological product, and 21 CFR 312.20 requires a sponsor to submit an IND before such an investigation begins [20]. ExaVeyra supplies exosome material for topical aesthetic use and for clinical research conducted under an IND, with the sponsor’s IND number confirmed before any supply.
What should a plastic surgeon exosome protocol include?: The supervising surgeon and each operator, the published topical sequence it follows, a statement that the material is applied topically after the procedure and nowhere else, the lot documents, the consent wording, the photography standard, the freezer log and the adverse event route. Kwon and colleagues described the resurfacing sequence in a double-blind split-face trial of 25 adults [11].
What do studies report about exosomes after surgery and other procedures?: The controlled human data are post-procedure and topical: Kwon and colleagues reported milder erythema and shorter downtime after fractional CO2 in 25 adults [11], and Park GH and colleagues reported higher improvement scores after microneedling in 28 adults [12]. Duncan and colleagues listed postprocedure recovery among the applications discussed in the 2026 surgical supplement [4], and Gaebe and colleagues rated the overall certainty low or very low [2].
Do accredited office surgery suites change the exosome question?: The facility rules the practice already follows carry over to the new step. Gupta and colleagues compared 183,914 aesthetic procedures and reported 30-day major complication rates of 1.3 percent in accredited office suites, 1.9 percent in ambulatory centers and 2.4 percent in hospitals [15], and state boards publish office surgery standards the practice registers under.
Are exosomes FDA approved for plastic surgery?: The FDA stated in 2019 that there are currently no FDA-approved exosome products [18], and its consumer alert states that exosome products intended to treat diseases or conditions in humans require FDA approval [19]. Abraham and Wilson wrote for facial plastic surgeons in 2025 that exosomes should be considered experimental until regulatory approval and robust clinical validation [16].
What exosome documentation should a plastic surgery practice keep?: The signed protocol, the sorted evidence file, the accreditation certificate, the lot documents read against MISEV2023 [17], a consent form that matches the website, the chart entry with the lot number, the freezer log and the adverse event route. Knauer and colleagues reported minimal processing information across 20 commercial products in 2026 [3].
How does a plastic surgery practice report an exosome adverse event?: Through the FDA’s MedWatch program, which accepts voluntary reports from health professionals covering biologics, devices and cosmetics, with the lot number in the report and the supplier notified [21]. Park KY described four women with persistent nodules and granulomatous inflammation after intradermal injection of products sold for topical use [14].

Continue Reading

Investigational Research

Exosomes With Energy-Based Devices: What the Research Shows

Channel types and closure times for each energy-based device, the vesicle trials after CO2, RF microneedling and picosecond lasers, and recovery endpoints.

Read article →

The monthly FDA and state law roundup

One email a month for licensed practices: FDA actions, compounding updates and state law changes that affect what you can source, each with its official source linked.

No spam. Unsubscribe any time.

For Clinics

Apply for Clinic Access

NPI-verified clinic access to our full catalog.

Apply for Clinic Access →

Sourcing Guide

Exosome Sourcing

What to look for: COA, particle count, and quality standards.

Read guide →

Compliance Guide

503A and 503B, Explained

How compounding pharmacies work, and what to ask before you order.